Vanguard Capital Management
BIO icon

Vanguard Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Vanguard Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$243M Sell
826,972
-4,193
-0.5% -$1.19M 0.01% 1017
2026
Q1 		$232M Buy
+831,165
New +$239M 0.01% 985

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management's BIO Position: Q2 2026 in Review

Vanguard Capital Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 0.5% in Q2 2026, selling an estimated $1.19M and leaving 826,972 shares worth $243M. The position accounts for 0.01% of the portfolio, ranked #1017.

Vanguard Capital Management first reported a position in BIO in Q1 2026 and has held it in 2 quarters since. 391 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Vanguard Capital Management held 826,972 shares of Bio-Rad Laboratories Class A worth $243M as of Q2 2026.
  • Vanguard Capital Management sold 4,193 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $1.19M.
  • Bio-Rad Laboratories Class A made up 0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1017 holding.
  • Vanguard Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2026 and has held it in 2 quarters since.
  • 391 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.